摘要
目的:观察NPC放疗中配合用CD3AK细胞治疗的效果。方法:将NPC分两组:A组72例(放疗+CD3AK细胞治疗),B组97例(单纯放疗)。治疗前后分别记录肿瘤情况,急性放射反应,Karnofsky氏评分,并检测外周血T淋巴细胞亚群和血清EB-VCA-IgA抗体水平。结果:①A、B二组肿瘤消除率分别是91.67%、87.63%,EB-VCA-IgA降低者分别占78%、69%。A、B组两项指标比较均无显著性差异(P>0.05);②急性放射反应A组明显比B组轻(P<0.01),Karnofsky氏评分A组比B组有所改善(P<0.05);③免疫指标:A组的CD+8比值下降,CD+3、CD+4、CD+4/CD+8比值均明显升高,而B组变化不大。结论:CD3AK细胞配合放疗治疗NPC安全可靠,与放疗有相加(协同)作用,可明显减轻急性放射反应,并有提高患者免疫功能的作用。
Objective:To observe the effect of the
combination of radiotherapy and CD3AK cells treatment on NPCMethods:Clinical trial was
conducted in 169 patients with NPC divided into group A(72 cases treated with
radiotherapy+CD3AK)and group B(97 cases treated with only radiotherapy)Before and after the
treatment,the conditions of the cases and their acute reaction to radiation were
recorded,Karnofsky's was used in the evaluation,and peripheral blood T cell subsets and the
levels of EBVCAIgA were determinedResults:1The improvement rate were 9167% and 8763%
respectively,and 78% and 69% of the patients showed reduction in EBVCAIgAThere was no
significant difference between group A and group B(P>005)2The acute reaction to radiation of
group A was significantly stronger than that of group B(P<001)Karnofsky's showed that group A
had better improvement than group B(P<005)3Immunological index:Group A's CD+8 ratio
decreased while its ratios of CD+3CD+4CD+4/CD+8 increases significantly,little difference was
shown in group BConclusion:Treatment with combination of CD3AK and radiotherapy proved
safe and effective for NPCThe combination could reduce acute reaction to radiation and enhance
patients' immunity
出处
《广西医学》
CAS
1999年第3期373-375,共3页
Guangxi Medical Journal